As per the Fact Sheet for Healthcare Providers provided by the US FDA on November 2020 and February 2021 granting emergency use authorization (EUA) for the use of casirivimab and imdevimab, bamlanivimab and etesevimab, and sotrovimab, adult and pediatric patients with mild to moderate COVID-19 illness are considered to be high risk if they meet at least one of the following criteria:

- ≥ 65 years of age

- Have underlying chronic kidney disease (CKD)

- Have underlying diabetes mellitus (DM)

- Have underlying immunosuppressive disease

- Are currently on immunosuppressive therapy

- Have a body mass index (BMI) ≥ 35 kg/m^2

- ≥ 55 years of age and have cardiovascular disease or hypertension or****COPD/other chronic respiratory diseases

- Aged between 12 to 17 years and****have a BMI ≥ 85 percentile for that age and gender-based on CDC growth charts, OR

- Have sickle cell disease, or****

- Have congenital or acquired heart disease, or

- Have neurodevelopmental disorders, or****

- Have dependence on a medical-related technology device (e.g., tracheostomy, gastrostomy on positive pressure ventilation unrelated to COVID-19, or

- Have underlying asthma, reactive airway, or chronic respiratory disease that requires daily medication for control.

**Authorized Dosages of Different Monoclonal Antibodies Against SARS-CoV-2**

**Casirivimab and Imdevimab**

- The authorized dosage under the FDA issued EUA is 1200 mg of casirivimab and 1200 mg of imdevimab administered together as a subcutaneous injection OR as a single IV infusion for 60 minutes in adults and pediatric patients (12 years of age and older weighing at least 40 kgs) who have a positive SARS-CoV-2 test and who had symptoms for ten days or less**.**

**Bamlanivimab and Etesevimab**

- The authorized dosage under the FDA issued EUA is 700 mg of bamlanivimab and 1400 mg of etesevimab administered together as a single IV infusion for 60 minutes in adults and pediatric patients (12 years of age and older weighing at least 40 kgs) who have a positive SARS-CoV-2 test and who had symptoms for ten days or less.

**Sotrovimab**

- The authorized dosage under the FDA issued EUA is 500 mg of sotrovimab by IV infusion over 30 minutes in adults and pediatric patients (12 years of age and older weighing at least 40 kgs) who have a positive SARS-CoV-2 test and who had symptoms for ten days or less and are at high risk for progression to severe COVID-19 disease.